Gufic Biosciences is currently trading at Rs. 200.10, up by 8.40 points or 4.38% from its previous closing of Rs. 191.70 on the BSE.
The scrip opened at Rs. 203.00 and has touched a high and low of Rs. 207.10 and Rs. 198.90 respectively. So far 201705 shares were traded on the counter.
The BSE group ‘B’ stock of face value Rs. 1 has touched a 52 week high of Rs. 215.45 on 17-May-2021 and a 52 week low of Rs. 52.10 on 21-May-2020.
Last one week high and low of the scrip stood at Rs. 215.45 and Rs. 175.80 respectively. The current market cap of the company is Rs. 1561.27 crore.
The promoters holding in the company stood at 65.75%, while Institutions and Non-Institutions held 8.47% and 25.77% respectively.
Gufic Biosciences has received permission from the Central Drugs Standard Control Organization, Ministry of Health And Family Welfare, New Delhi to manufacture and market Liposomal Amphotericin B Injection 50mg/vial (Lyophilized), subject to the conditions prescribed in Chapter X of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.
The said injection is used to treat cases of Mucormycosis, also called as Black Fungus that damages the nose, eyes, sinuses, and sometimes even the brain. Mucormycosis is a very rare infection which is caused by exposure to mucor mould which is commonly found in soil, plants, manure, and decaying fruits and vegetables and it affects the sinuses, the brain and the lungs and can be life-threatening in diabetic or severely immunocompromised individuals, such as cancer patients or people with HIV/AIDS.
Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.